“The newly named acting commissioner of the Food and Drug Administration (FDA) is poised to take over at a crucial time for the agency, as outgoing Commissioner Scott Gottlieb leaves an ambitious legacy largely unfinished.”
“President Trump’s decision to tap Norman Sharpless as acting commissioner of the FDA is drawing praise from health advocates, who see it as an opportunity for the agency to continue its work uninterrupted…”
An analysis by investment firm Cowen and Company said FDA is currently viewed “as operating at peak efficiency during an unprecedented innovation period.” But the analysis cautioned that Sharpless is taking over “where all the risks are on the down side if the agency is unable to match very high bar metrics of success going forward…” Read the full article here.
Source: FDA faces test under new chief – By Nathaniel Weixel, March 14, 2019. The Hill.
